Nrf2-mediated oxidative stress pathways are shared among LN, diabetic nephropathy, IgA nephropathy, and other disorders, indicating that targeting Nrf2 expression may be critical to successful LN therapy (7). The gene discussed is NFE2L2; the disease is IgA glomerulonephritis.